<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report the results of the protocol CMA (<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, Aracytine) reinforced of 26 patients affected by Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in facial-maxillary localisation, in a retrospective study from January 2000 till December 2007 and prospective from January till September 2008 </plain></SENT>
<SENT sid="1" pm="."><plain>Their average age was 7.89 years, with a sex ratio of 2.71 </plain></SENT>
<SENT sid="2" pm="."><plain>The global response to the treatment was 92.3% with 57.7% of complete remission and 34.6% of incomplete remission </plain></SENT>
<SENT sid="3" pm="."><plain>The morbidity related to treatment was essentially a haematological complication (84.6%) and hydroelectrolytic complication (84.6%) </plain></SENT>
<SENT sid="4" pm="."><plain>Evolution was made towards <z:hpo ids='HP_0011420'>death</z:hpo> in 30.8 and 15.4% were lost of view </plain></SENT>
<SENT sid="5" pm="."><plain>The median monitoring was 18.2 months </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment response was linked to the therapeutic compliance (P &lt; 0.001), and the delay of consultation (P = 0.01) </plain></SENT>
</text></document>